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In spite of the clinical usefulness of cisplatin (CDDP), there are many occasions in which it is difficult to continue the administration of
CDDP due to its nephrotoxicity and neurotoxicity. We examined the incorporation of CDDP into polymeric micelles to see if this
allowed the resolution of these disadvantages. Cisplatin was incorporated into polymeric micelles through the polymer–metal
complex formation between polyethylene glycol poly(glutamic acid) block copolymers and CDDP (NC-6004). The
pharmacokinetics, pharmacodynamics, and toxicity studies of CDDP and NC-6004 were conducted in rats or mice. The particle
size of NC-6004 was approximately 30nm, with a narrow size distribution. In rats, the area under the curve and total body clearance
values for NC-6004 were 65-fold and one-nineteenth the values for CDDP (Po0.001 and 0.01, respectively). In MKN-45-implanted
mice, NC-6004 tended to show antitumour activity, which was comparable to or greater than that of CDDP. Histopathological and
biochemical studies revealed that NC-6004 significantly inhibited the nephrotoxicity of CDDP. On the other hand, blood
biochemistry revealed transient hepatotoxicity on day 7 after the administration of NC-6004. Furthermore, rats given CDDP showed
a significant delay (Po0.05) in sensory nerve conduction velocity in their hind paws as compared with rats given NC-6004. Electron
microscopy in rats given CDDP indicated the degeneration of the sciatic nerve, but these findings were not seen in rats given NC-
6004. These results were presumably attributable to the significantly reduced accumulation of platinum in nerve tissue when NC-
6004 was administered (Po0.05). NC-6004 preserved the antitumour activity of CDDP and reduced its nephrotoxicity and
neurotoxicity, which would therefore seem to suggest that NC-6004 could allow the long-term administration of CDDP where
caution against hepatic dysfunction must be exercised.
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Cisplatin (cis-dichlorodiammineplatinum (II): CDDP) is a key
drug in the chemotherapy for cancers, including lung, gastro-
intestinal, and genitourinary cancer (Roth, 1996; Boulikas and
Vougiouka, 2004). However, we often find that it is necessary to
discontinue treatment with CDDP due to its adverse reactions, for
example, nephrotoxicity and neurotoxicity, despite its persisting
effects (Pinzani et al, 1994). Platinum (Pt) analogues, for example,
carboplatin and oxaliplatin (Cleare et al, 1978), have been
developed to date to overcome these CDDP-related disadvantages.
Consequently, these analogues are becoming the standard drugs
for ovarian cancer (du Bois et al, 2003) and colon cancer (Cassidy
et al, 2004). However, those regimens including CDDP are
considered to constitute the standard treatment for lung cancer,
stomach cancer, testicular cancer (Horwich et al, 1997), and
urothelial cancer (Bellmunt et al, 1997). Therefore, the develop-
ment of a drug delivery system (DDS) technology is anticipated,
which would offer the better selective accumulation of CDDP
into solid tumours while lessening its distribution into normal
tissue.
Drug delivery system targeting involves two concepts: active
targeting and passive targeting. Active targeting aims drug
targeting through antigen–antibody reactions and specific bind-
ings between molecules, for example, receptor and ligand. On the
other hand, passive targeting is an approach in which the drug
accumulates in tumour tissue using the pathophysiological
characteristics of solid tumours such as the hyperplasia of tumour
vasculature which generally occurs in solid tumours, but which is
not seen in a comparable way in lymph nodes. Marked vascular
hyperpermeability is also found in the tumour vasculature, and
the combination of hyperplasia and hyperpermeability facilitate
the extravasation of high-molecular-weight polymers or nano-
particles, which are less prone to leak from intact vasculature, and
which can be retained in solid tumour tissue for a longer time
(enhanced permeability and retention effect (EPR) effect) (Matsu-
mura and Maeda, 1986; Maeda and Matsumura, 1989; Maeda, 2000,
2001). This effect allows passive targeting of macromolecules with
a high blood retention profile into the site of tumour.
Simple polymerisation only is not sufficient to bring about the
EPR effect, and strategies are also required to suppress trapping by
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sthe reticuloendothelial system (RES) and to enhance the blood
retention profile (Klibanov et al, 1990, 1991; Allen, 1994; Gabizon
etal, 1996; Lasic, 1996). Polyethylene glycol-tagged liposomal
adriamycin (Doxil
s) has recently been reported as a clinical
success (Orditura etal, 2004). We have recently been conducting
research dedicated to the development of polymeric micelles
capable of incorporating anticancer drugs (Yokoyama et al, 1990,
1991, 1999). The Phase I clinical trial of adriamycin-incorporating
polymeric micelles has been completed (Matsumura et al, 2004).
Furthermore, in an animal model, the plasma and tumour area
under the curve (AUC) values for taxol-incorporating polymeric
micelle (NK105) showed 85- and 25-fold increases, respectively,
as compared with those for taxol. Therefore, NK105 showed
significant enhancement (Po0.001) of the antitumour activity of
free taxol and a significant reduction (Po0.05) in its neurotoxicity
(Hamaguchi et al, 2005). Based on these results, the Phase I clinical
trial of NK105 is currently being conducted at the National Cancer
Center Hospital, Tokyo. We have also been conducting research
dedicated to the development of CDDP-incorporating polymeric
micelles and have made a number of improvements, in the in vivo
antitumour activity, reduction of nephrotoxicity, particle size,
and particle size distribution as variables (Nishiyama and Kataoka,
2001; Nishiyama et al, 2001). Consequently, we discovered that
block copolymers, which react with CDDP, acquire a long blood
retention profile with the use of polyethylene glycol poly(glutamic
acid) block copolymers (PEG–P(Glu)) (Nishiyama et al, 2003). In
the present study, we used the final development of the technology
to prepare CDDP-incorporating polymeric micelles (NC-6004) in
an attempt to investigate the following objectives: (1) calculation of
pharmacokinetic (PK) parameters in a detailed PK study of CDDP
and NC-6004 in rats; (2) a comparison between CDDP and NC-
6004 with respect to their antitumour activity in a human cancer
cell line; and (3) a detailed comparison between CDDP and NC-
6004 with respect to nephrotoxicity and neurotoxicity, which
constitute the dose-limiting factors of CDDP.
MATERIALS AND METHODS
Materials
Cisplatin was purchased from WC Heraeus GmbH & Co., KG
(Hanau, Germany). g-Benzyl-L-glutamate N-carboxy anhydride
was purchased from a supplier. N,N-dimethylformamide and 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide were
purchased from Wako Pure Chemical Co., Inc. (Osaka, Japan).
a-Methoxy-o-aminopropyl polyethylene glycol (CH3O–PEG–
CH2CH2CH2–NH2;M W ¼12000) was purchased from NOF
Corporation (Tokyo, Japan).
Following cell lines, MKN-45, MKN-28, EJ-1, J82, MBT-2,
colo201, colo320, HT-29, A549, EBC-1, PC-14, and MCF-7 cells
were purchased from the American Type Culture Collection.
Female BALB/c nu/nu mice were purchased from SLC (Shizuoka,
Japan). Female Sprague–Dawley rats were purchased from Charles
River Japan (Kanagawa, Japan). All animal procedures were
performed in compliance with the guidelines for the care and
use of experimental animals, which had been drawn up by the
Committee for Animal Experimentation at the National Cancer
Center; these guidelines meet the ethical standards required by law
and also comply with the guidelines for the use of experimental
animals in Japan and the UKCCCR guidelines (UKCCCR, 1998).
Preparation of PEG-P(Glu) and preparation of CDDP-
incorporating polymeric micelles (NC-6004)
Polyethylene glycol–P(Glu) block copolymers were synthesised
according to the slightly modified procedure of the previously
reported synthetic method of PEG-P(Asp) (Nishiyama and
Kataoka, 2001). g-Benzyl L-glutamate N-carboxy anhydride was
polymerised in N,N-dimethylformamide, initiated with the NH2
amino group of CH3O–PEG–CH2CH2CH2NH2, to obtain PEG–
poly(g-benzyl L-glutamate) block copolymers (PEG–PBLG).
The polymerisation degree of PBLG was determined to be
40 by comparing proton ratios between PEG ( OCH2CH2–:
d¼3.7p.p.m.) and phenyl groups of PBLG ( CH2C6H5:
d¼7.3p.p.m.) in
1H NMR measurement (Mercury plus 300 (Varian
Technologies); solvent: DMSO-d6; and temperature: 251C). The
benzyl group was deprotected by mixing with 0.5 N NaOH at
ambient temperature to obtain PEG–P(Glu) as a sodium salt.
Cisplatin-incorporating polymeric micelles (NC-6004) were
prepared according to the slightly modified procedure of the
previously reported synthetic method of CDDP-incorporating
polymeric micelles (Nishiyama et al, 2003). Briefly, the sodium
salt of PEG–P(Glu) and CDDP were dissolved in distilled water
([Glu]¼4.7mmoll
 1; [CDDP]/[Glu]¼1.0) and were allowed to
react for 72h. NC-6004 thus prepared was purified with
ultrafiltration (molecular weight cutoff size: 100000). The size
distribution of NC-6004 was evaluated by dynamic light scattering
(DLS) at 231C using the NICOMP 380 ZLS particle sizer (Particle
Sizing Systems, Santa Barbara, CA).
Release of CDDP from NC-6004 dissolved in saline
NC-6004 was dissolved in saline and was then incubated at 371C. In all,
80ml of the solution was then harvested at 3, 6, 24, and 96h after the
onset of incubation. The release of CDDP from NC-6004 in the solution
harvested at 371C was quantified by gel permeation chromatography
(column: Waters Ultrahydrogel 500 (f7.8 300mm); Waters GPC
system equipped with a UV detector (310nm); and eluent: 10mmoll
 1
phosphate-buffered 50mmoll
 1 NaCl solution).
In vitro cytoxicity
Various human cancer cell lines were evaluated in the present
study. The cell lines were maintained in monolayer cultures in
Dulbecco’s modified Eagle’s medium containing 10% (vv
 1) focal
calf serum and 600mgl
 1 glutamine. WST-8 Cell Counting kit-8
(Dojindo, Kumamoto, Japan) was used for cell proliferation assay.
In all, 2000 cells of each cell line in 90ml of culture medium were
plated in 96-well plates and were then incubated for 24h at 371C.
Serial dilutions of CDDP and NC-6004 in a volume of 10ml were
added, and the cells incubated for 48 or 72h. All dates were
expressed as mean7s.e. of triplicate of the date triplicate cultures.
The data were then plotted as a percentage of the data from the
control cultures, which were treated identically to the experimental
cultures, except that no drug was added.
Pharmacokinetics and pharmacodynamics of CDDP and
NC-6004
Under isoflurane anaesthesia, a polyethylene catheter was inserted
into the right internal jugular vein of female Sprague–Dawley
female rats. Rats (n¼3) were given a single intravenous (i.v.)
injection of CDDP (5mgkg
 1) or NC-6004 (an equivalent dose of
5mgkg
 1 CDDP) via the tail vein. At 5, 15, and 30min, as well as
at 1, 4, 12, 24, and 48h after injection of each drug, blood (0.2ml)
was collected into a heparinised microtube via the polyethylene
catheter. The blood samples were centrifuged (1000g) for 10min at
room temperature to obtain the plasma. The plasma samples were
stored below  801C until the analysis. In a tissue distribution
study, rats were injected i.v. with CDDP (5mgkg
 1) or NC-6004
(an equivalent dose of 5mgkg
 1 CDDP) via the tail vein, and
were then killed in groups of three animals at 10min, at 1, 6, 24,
and 48h, and on day 7 day after injection of each drug under
intraperitoneal pentobarbital anaesthesia (50mgkg
 1). Various
organs (kidney, liver, spleen, heart, lung, small intestine, colon,
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sand stomach) were dissected. The organ samples were stored below
 801C until the analysis. Female BALB/c mice were inoculated
subcutaneously on the back with 10
6 MKN-45 cells (UKCCCR,
1998). After 10 days, when the tumour size had reached
approximately 50mm
2, mice were injected i.v. with CDDP
(5mgkg
 1) or NC-6004 (an equivalent dose of 5mgkg
 1 CDDP)
via the tail vein and were then killed in groups of three animals at
10min, at 1, 6, 24, and 48h, and on day 7 after injection of each
drug. The tumours were dissected and stored below  801C until the
analysis. The plasma samples were diluted with 0.1 N HCl, vortexed,
and analysed for elemental Pt by frameless atomic absorption
spectrophotometry (FAAS). The tissue samples were decomposed
by heating in concentrated nitric acid, evaporated to dryness, and
redissolved in 0.1 N HCl. Elemental Pt was measured by FAAS.
The PK parameters were calculated using noncompartmental
analysis (WinNonlin standard software, version 3.1; Pharsight
Corporation, Palo Alto, CA, USA). The following PK parameters
were obtained: AUC, maximum Pt concentration (Cmax), time to
obtain Cmax (Tmax), total body clearance (CLtot), terminal half-life
of Pt (t1/2z), and steady-state volume of distribution (Vss). The area
under the tumour concentration–time curve (tumour AUC) was
calculated based on the trapezoidal rule up to 48h. The parameters
were calculated using the following equations:
AUC0 t
was calculated by the trapezoidal rule to the last measurable data
point:
AUC0 inf : ¼
Z 1
0
CðtÞdt
t1=2zðterminalhalf-lifeÞ¼0:693=lz
lz: first-order rate constant associated with terminal portion of the
curve)
CLtot ¼ Dose=AUC0 inf :
Vss ¼ MRT CLtotðMRT : meanresidencetimeÞ
In vivo antitumour activity
Antitumour activity was evaluated using nude mice implanted with
a human gastric cancer cell line MKN-4. BALB/c nu/nu female
mice (aged 6 weeks) were inoculated subcutaneously with 10
6
MKN-45 cells on the right dorsal skin. After 3 days, when tumour
diameter had reached approximately 3mm, tumour-bearing mice
were allocated randomly to drug administration groups of six
animals each. The drugs were administered as follows: animals in
the CDDP group were given doses of 0.5, 2.5, 5mgkg
 1; animals in
the NC-6004 group were given doses of 0.5, 2.5, and 5mgkg
 1; and
animals in the control group were given the 5% glucose solution.
Cisplatin or NC-6004 was administered to mice at any of the above
dose levels per dose every 3 days. Antitumour activity was
evaluated in terms of tumour size by measuring two orthogonal
diameters (a b: a, long diameter; b, short diameter) at various
time points. Animals were killed by cervical dislocation when
the tumour size reached approximately 15mm (UKCCCR, 1998).
Changes in body weight were also monitored for the mice which
were used in the present study.
Nephrotoxicity and hepatotoxicity of CDDP and NC-6004
Under isoflurane anaesthesia, five groups of Sprague–Dawley
female rats (aged 6 weeks; 185–215g initial body weight) were
given a single i.v. injection of 5% glucose (n¼8), CDDP at a dose
of 10mgkg
 1 (n¼12), NC-6004 at a dose of 10mgkg
 1 on a
CDDP basis (n¼13), or NC-6004 at a dose of 15mgkg
 1 on a
CDDP basis (n¼8). Samples of blood and major organs were
taken on day 7 after administration (UKCCCR, 1998). In the case
of administering NC-6004 at a dose of 10mgkg
 1 on a CDDP
basis, five samples of blood and major organs were taken on day 14
after administration. The organs were immersed in 10% formalin
solution. In each blood sample, plasma concentrations of blood
urea nitrogen (BUN), creatinine, glutamic oxaloacetic trans-
aminase (GOT), and glutamic pyruvic transaminase (GPT) were
measured by SRL Laboratories (Tokyo, Japan). In addition, WBC
and platelet were counted for blood samples 7 and 14 days after
each drug administration in SRL Laboratories (Tokyo, Japan).
Evaluation of neurotoxicity
The severity of neurotoxicity was assessed by electrophysiological
and histopathological procedures. Under isoflurane anaesthesia, rats
(n¼5) were given CDDP (2mgkg
 1), NC-6004 (an equivalent dose
of 2mgkg
 1 CDDP), or 5% glucose, all i.v., twice a week, to a total
of 11 administrations. Electrophysiological measurements were
conducted at week 6 after the first administration, using the method
described previously (McKeage et al, 1994; Screnci et al, 2000).
Under light anaesthesia with phenobarbital, responses were evoked
by stimulating the sciatic nerve at its notch and the tibial nerve at
the ankle of the right hind paw, using a percutaneous needle
electrode. The plantar muscle H- and M-waves were recorded using
a pair of superficial silver–silver chloride electrodes applied to the
sole and dorsum of the hind paw. H-response-related sensory nerve
conduction velocity (SNCV) was calculated by dividing the distance
between the stimulation sites at the sciatic notch and ankle by the
difference in H-response latency after stimulation at the ankle and
sciatic notch. M-response-related motor nerve conduction velocity
(MNCV) was calculated by dividing the distance between the
stimulation sites at the sciatic notch and ankle by the difference in
M-response latency after stimulation at the sciatic notch and ankle.
At week 7 after the initial administration, rats under deep
anaesthesia with phenobarbital were subjected to intracardiac
catheterisation and were rinsed with saline, followed by perfusion
with 4% glutaraldehyde in 0.12M PBS. Subsequently, a segment of
the sciatic nerve was carefully removed. One part of the sciatic nerve
w a sp o s t - f i x e dw i t h4 %g l u t a r a l d e h y d ei n0 . 1 2 M PBS for 24h and
was then embedded in epoxy resin as described previously
(Cavaletti et al, 1992). The remaining parts of the sciatic nerve
were immersed in a 10% formalin solution. Semi-thin (1mmt h i c k )
and thin sections were prepared from the resin-embedded sciatic
nerve for light microscopic observation and electron microscopic
observation, respectively.
To determine the Pt concentration in the sciatic nerve, rats were
given CDDP (5mgkg
 1, n¼5), NC-6004 (an equivalent dose of
5mgkg
 1 CDDP, n¼5), or 5% glucose (n¼2), all i.v. twice a
week, to a total of four administrations. On day 3 after the final
administration, a segment of the sciatic nerve was removed. The
removed sciatic nerve was prepared for ICP-MS analysis as
described previously (Screnci et al, 2000). Briefly, the nerve was
immersed in 1ml of 70% nitric acid overnight. On the next day, the
nerve was digested for 2h at 901C and Milli-Q was then added to a
final volume of 5ml. Finally, the Pt concentration in the sample
solution was analysed with an ICP-MS spectrometer (SPQ 9000;
Seiko Instruments Inc., Tokyo, Japan).
Statistical analysis
Data on therapeutic efficacy and body weight change were
expressed as the mean7s.e. The other data were expressed as
the mean7s.d. The statistical significance of differences in
therapeutic efficacy and body weight change between two
administration groups was calculated by repeated-measured
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sanalysis of variance (ANOVA). The statistical significance of
differences in other data between two administration groups was
calculated with the Student’s t-test. All data were calculated with
StatView
s Software, version 5 (ABACUS Concepts, Berkeley, CA).
A value of Po0.05 was considered statistically significant.
RESULTS
Preparation and characterisation of CDDP-incorporating
polymeric micelles (NC-6004)
Cisplatin-incorporating polymeric micelles (NC-6004) consist of
CDDP and PEG–P(Glu) (Figure 1A). Furthermore, NC-6004
consists of PEG, a hydrophilic chain which constitutes the outer
shell of the micelles, and the coordinate complex of P(Glu) and
CDDP, a polymer–metal complex-forming chain which constitutes
the inner core of the micelles. The molecular weight of PEG–
P(Glu) as a sodium salt was approximately 18000 (PEG: 12000;
P(Glu): 6000). The CDDP-incorporated polymeric micelles were
clearly discriminated from typical micelles from amphiphilic block
copolymers. The driving force of the formation of the CDDP-
incorporated micelles is the ligand substitution of Pt(II) atom from
chloride to carboxylate in the side chain of P(Glu). The molar ratio
of CDDP to the carboxyl groups in the copolymers was 0.71
(Nishiyama et al, 2003). A narrowly distributed size of polymeric
micelles (30nm) was confirmed by the DLS measurement
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Figure 1 Preparation and characterisation of CDDP-incorporating polymeric micelles (NC-6004). (A) Chemical structures of CDDP and PEG–P(Glu)
block copolymers, and the micellar structures of CDDP-incorporating polymeric micelles (NC-6004). (B) The particle size distribution of NC-6004 measured
by the dynamic light-scattering method. The mean particle size of NC-6004 was approximately 30nm. (C) Release of CDDP from NC-6004 in saline at 371C.
Table 1 Pharmacokinetic parameter estimates for CDDP and NC-6004 in rats (see text for definitions of parameters)
Compound Rat Tmax
a (h)
Cmax
a
(lgml
 1) t1/2z (h)
AUC0–t
(lghml
 1)
AUC0–inf.
(lghml
 1)
CLtot
(mlh
 1kg
 1)
MRT0–inf.
(h)
Vss
(lkg
 1)
CDDP Mean s.d. 0.083 11.67 34.50 20.47 75.73 70.67 46.57 3.00
0.57 16.14 2.25 26.13 20.34 22.38 0.61
NC-6004 Mean s.d. 0.50 89.90 6.43 1325.90 1335.47 3.77 10.67 0.04
4.29 0.55 77.85 75.99 0.21 0.15 0.0023
The pharmacokinetic parameters were calculated after fitting to a noncompartment model using WinNonlin program.
aFor CDDP group, Tmax represents time of maximum
concentration.
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s(Figure 1B). Also, the static light scattering (SLS) measurement
revealed that the CDDP-loaded micelles showed no dissociation
upon dilution and the CMC was less than 5 10
 7, suggesting
remarkable stability compared with typical micelles from amphi-
philic block copolymers (Nishiyama et al. 1999). It is assumed that
the interpolymer crosslinking by Pt(II) atom might contribute to
stabilisation of the micellar structure.
The release rates of CDDP from NC-6004 were 19.6 and 47.8% at
24 and 96h, respectively (Figure 1C). Therefore, the release of
CDDP was as slow as the previously reported release (Nishiyama
et al, 2003). In distilled water, furthermore, NC-6004 was stable
without releasing CDDP (data not shown).
Pharmacokinetics and pharmacodynamics
Frameless atomic absorption spectrophotometry could measure
serum concentrations of Pt up to 48h after i.v. injection of NC-
6004, but could measure them only up to 4h after i.v. injection
of CDDP. NC-6004 showed a very long blood retention profile
as compared with CDDP. The AUC0 t and Cmax values were
significantly higher in animals given NC-6004 than in animals given
CDDP, namely, 65- and 8-fold, respectively (Po0.001 and 0.001,
respectively) (Table 1, Figure 2A). Furthermore, the CLtot and Vss
values were significantly lower in animals given NC-6004 than in
animals given CDDP, that is, one-nineteenth and one-seventy-fifth,
respectively (Po0.01 and 0.01, respectively) (Table 1).
Regarding the concentration–time profile of Pt in various
tissues after i.v. injection of CDDP or NC-6004, all organs
measured exhibited the highest concentrations of Pt within 1h
after administration in all animals given CDDP (Figure 2B).
Furthermore, animals given NC-6004 exhibited the highest tissue
concentrations of Pt in the liver and spleen at late time points (24
and 48h after administration, respectively). However, the con-
centrations decreased on day 7 after administration (Figure 2C). In
addition, and in a similar manner to other drugs which are
incorporated in polymeric carriers, NC-6004 demonstrated accu-
mulation in organs of the reticuloendothelial system, for example,
liver and spleen. At 48h after administration, tissue concentrations
of Pt in the liver and spleen were 4.6- and 24.4-fold higher for
NC-6004 than for CDDP. On the other hand, a marked increase
in tissue Pt concentration was observed immediately after
administration in the kidneys of animals given CDDP. Renal Pt
concentration at 10min and 1h after administration were 11.6-
and 3.1-fold lower, respectively, in animals given NC-6004 than in
animals given CDDP. Furthermore, the maximum concentration
(Cmax) in the kidney was 3.8-fold lower at the time of NC-6004
administration than at the time of CDDP administration.
Regarding the tumour accumulation of Pt, tumour concentra-
tions of Pt peaked at 10min after administration of CDDP. On the
other hand, tumour concentrations of Pt peaked at 48h after
administration of NC-6004 (Figure 2D). The maximum concentra-
tion (Cmax) in tumour was 2.5-fold higher for NC-6004 than for
CDDP (Po0.001). Furthermore, the tumour AUC was 3.6-fold
higher for NC-6004 than for CDDP (81.2 and 22.6mgmlh
 1 in
animals given NC-6004 and CDDP, respectively).
In vitro cytotoxicity
NC-6004 was tasted on 12 human tumour cell lines derived from
bladder, colon, lung, gastric, and breast cancers. The IC50 values of
NC-6004 were 6-to 15-fold higher than those of CDDP (Table 2).
In vivo antitumour activity
BALB/c nude mice implanted with a human gastric cancer cell line
MKN-45 showed decreased tumour growth rates after i.v. injection
of CDDP and NC-6004 (Figure 3A). In the administration of CDDP,
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Figure 2 Time profiles of Pt concentration in the plasma and tissue
distribution of Pt after a single i.v. injection of CDDP (5mgkg
 1) or NC-
6004 (an equivalent dose of 5mgkg
 1 CDDP). (A) Concentration–time
profile of Pt in the plasma after a single i.v. injection of CDDP (K) and NC-
6004 (J) in rats (n¼3). Tissue distribution of Pt after a single i.v. injection
of CDDP (B) and NC-6004 (C) in rats (n¼3) (kidney ( ), liver (&),
spleen ( ), and lung (’)). (D) Time profiles of Pt concentration in the
MKN-45 solid tumour after a single i.v. injection of CDDP (’) and NC-
6004 (&) in MKN-45 bearing BALB/c nude mice (n¼3). Values are
expressed as the mean7s.d.
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sthe CDDP 5mgkg
 1 administration group showed a significant
decrease (Po0.01) in tumour growth rate as compared with the
control group. In the administration of NC-6004, NC-6004
2.5mgkg
 1 administration group (Po0.05) and 5mgkg
 1 adminis-
tration group (Po0.01) showed significant decreases in tumour
growth rate as compared with the control group. However, the
NC-6004 administration groups at the same dose levels as CDDP
showed no significant difference in tumour growth rate. The same
animal model was used to repeat the study using the drugs at
different dose levels, and similar tendencies were observed (data
not shown). Regarding time-course changes in body weight change
rate, the CDDP 5mgkg
 1 administration group showed a
significant decrease (Po0.001) in body weight as compared with
the control group. On the other hand, none of the NC-6004
administration groups showed a decrease in body weight as
compared with the control group (Figure 3B).
Nephrotoxicity and hepatotoxicity of CDDP and NC-6004
In the CDDP 10mgkg
 1 administration group, four of 12 animals
died from toxicity within 7 days after drug administration. No
deaths occurred in the NC-6004 10mgkg
 1 administration group
and the NC-6004 15mgkg
 1 administration group. Regarding
renal function, the BUN concentrations on day 7 after the
administration of 5% glucose, CDDP 10mgkg
 1, NC-6004
10mgkg
 1, and NC-6004 15mgkg
 1 were 20.873.0, 65.3744.4,
2074.5, and 24.6718.2mgdl
 1, respectively. The plasma concen-
trations of creatinine on day 7 after the administration of 5%
glucose, CDDP 10mgkg
 1, NC-6004 10mgkg
 1, and NC-6004
15mgkg
 1 were 0.2770.03, 0.6870.23, 0.2870.04, and
0.4570.11mgdl
 1, respectively. The CDDP 10mgkg
 1 adminis-
tration group showed significantly higher plasma concentrations
of BUN and creatinine as compared with the control group
(Po0.05 and 0.001, respectively), with the NC-6004 10mgkg
 1
administration group (Po0.05 and 0.001, respectively), and also
with the NC-6004 15mgkg
 1 administration group (Po0.05 and
0.05, respectively) (Figure 4A and B). Light microscopy indicated
tubular dilation with flattening of the lining cells of the tubular
epithelium in the kidney from all animals in the CDDP 10mgkg
 1
administration group. On the other hand, no histopathological
change was observed in the kidneys from all animals in the
NC-6004 10mgkg
 1 administration group (Figure 4C and D).
Regarding hepatic function, the plasma concentrations of GOT on
day 7 after the administration of 5% glucose, CDDP 10mgkg
 1,
NC-6004 10mgkg
 1, and NC-6004 15mgkg
 1 were 6876.8,
65.175.5, 106713.1, and 97716.2IUl
 1, respectively. The plasma
concentrations of GPT on day 7 after the administration of
5% glucose, CDDP 10mgkg
 1, NC-6004 10mgkg
 1, and NC-6004
15mgkg
 1 were 39.6710, 3276.4, 92718.9, and 55711.3IUl
 1,
respectively. The CDDP 10mgkg
 1 administration group showed
plasma concentrations of GOT and GPT which were comparable
to those in the control group. However, the NC-6004 10mgkg
 1
administration group, which presented the same dose level as the
CDDP 10mgkg
 1 administration group, showed significantly
higher plasma concentrations of GOT and GPT (Po0.001 and
0.01, respectively) as compared with the control group. Further-
more, the NC-6004 15mgkg
 1 administration group also showed
significantly higher plasma concentrations of GOT (Po0.001) as
compared with the control group. However, the plasma concen-
trations of GOT and GPT on day 14 after the administration of
NC-6004 10mgkg
 1 were comparable to those in the control group
(7472.3 and 42.875.1IUl
 1, respectively) (Figure 4E). These
results lead to the conjecture that rats which were given NC-6004
10mgkg
 1, i.v., showed transient and reversible hepatotoxicity.
Table 2 IC50 values(mM) of CDDP and NC-6004 in various cancer cell
lines
Exposure time (h)
48 72
Cancer Cell line CDDP NC-6004 CDDP NC-6004
Bladder cancer EJ-1 2.46 25.45 1.86 18.44
J82 2.78 42.89 2.42 20.27
MBT-2 15.88 4100 5.67 71.67
Colon cancer Colo201 34.77 4100 28.52 4100
Colo320 16.32 4100 9.71 81.15
HT-29 14.44 4100 8.83 4100
Lung cancer A549 21.43 4100 20 4100
EBC-1 4100 4100 9.36 84.78
PC-14 16.81 4100 8.73 87.11
Gastric cancer MKN-28 4100 4100 8.23 76.81
MKN-45 7.12 68.36 6.94 43.81
Breast cancer MCF-7 12.78 4100 5.71 54.71
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Figure 3 Relative changes in MKN-45 tumour growth rates in nude
mice. (A) Cisplatin and NC-6004 were injected i.v. every 3 days, three
administrations in total, at CDDP-equivalent doses of 0.5mgkg
 1 (K, J),
2.5mgkg
 1 (m, n), and 5mgkg
 1 (’, &), respectively. Glucose (5%) was
injected in the control mice ( ). (B) Changes in relative body weight. Data
were derived from the same mice as those used in the present study.
Values are expressed as the mean7s.e.
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sNeurotoxicity of CDDP and NC-6004
Neurophysiological examination revealed that MNCVs in animals
given 5% glucose, CDDP, and NC-6004 were 44.273.5,
40.9475.08, and 40.6270.63ms
 1, respectively. No significant
difference was found among the groups with respect to MNCV.
Furthermore, SNCVs in animals given 5% glucose, CDDP, and
NC-6004 were 42.8678.07, 35.4874.91, and 43.7475.3ms
 1,
respectively. Animals given NC-6004 showed no delay in SNCV
as compared with animals given 5% glucose. On the other hand,
animals given CDDP showed a significant delay (Po0.05) in SNCV
as compared with animals given NC-6004 (Figure 5A). In addition,
histopathological examination with electron microscopy revealed
degenerations, as manifested by electron photomicrographs
indicating degenerative changes, for example, loss of microtubules,
degeneration in the cytoplasm of Schwann cells, loss of filaments,
and an irregular inner loop, in approximately 80% of myelinated
segments of the sciatic nerve from animals given CDDP. On the
other hand, animals given NC-6004 exhibited nearly normal
electron photomicrographs of the sciatic nerve as the control
animals did (Figure 5B and C). These results indicate that NC-6004
reduced peripheral neurotoxicity as compared with CDDP.
Furthermore, regarding body weight change as an indication of
general toxicity, furthermore, the NC-6004 administration groups
showed significant inhibition of body weight decrease (Po0.001)
as compared with the CDDP administration group (Po0.001)
(Figure 5D).
The analysis by ICP-MS on sciatic nerve concentrations of Pt
could not detect Pt in the sciatic nerve from animals given 5%
glucose (data not shown). Sciatic nerve concentrations of Pt in
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Figure 4 Nephrotoxicity and hepatotoxicity of CDDP and NC-6004. Plasma concentrations of BUN (A) and creatinine (B) were measured after a single
i.v. injection of 5% glucose (&)( n¼8), CDDP at a dose of 10mgkg
 1 (’)( n¼12), NC-6004 at a dose of 10mgkg
 1 (n¼13) on a CDDP basis ( ), and
at a dose of 15mgkg
 1 on a CDDP basis ( )( n¼8) to rats. Histopathological changes in the kidney on day 7 after the i.v. injection of CDDP (C,  4) and
NC-6004 (D,  4) in rats at an equivalent dose of 10mgkg
 1 CDDP. In rats given CDDP, widespread tubular degeneration as indicated by tubular dilation
with flattening of the lining cells of tubular epithelium was seen. On the other hand, no histopathological change was observed in the kidney from all animals
in the NC-6004 10mgkg
 1 administration group. For hepatotoxicity (E), the plasma concentrations of GOT and GPT were measured on day 7 after
administration. When administering NC-6004 at a dose of 10mgkg
 1 on a CDDP basis, five of 13 blood samples were taken on day 14 after administration
( ). The other samples were taken on day 7 administration. In the group given CDDP at a dose of 10mgkg
 1, four of 12 rats died within 7 days. Values are
expressed as the mean7s.d. *Po0.05, **Po0.001, NS: not significant.
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395.5773.1ngg
 1 tissue. Therefore, the concentrations were
significantly (Po0.05) lower in animals given NC-6004
(Figure 5E). This finding is believed to be a factor which reduced
neurotoxicity following NC-6004 administration as compared with
the CDDP administration.
DISCUSSION
The present study indicated that CDDP-incorporating polymeric
micelles (NC-6004) are stable nanoparticles with a long blood
retention profile as compared with free CDDP. NC-6004 showed
6- to 15-fold less potent in vitro cytotoxic activity in several human
cancer cell lines as compared with CDDP. These findings are
considered attributable to the slow release of free CDDP in the
presence of abundant chloride ions because NC-6004 contains
coordination bonds between the atoms of Pt(II) of CDDP and the
carboxylic group in the side chain of P(Glu). In vivo, however, in
contrast to the in vitro findings, NC-6004 was found to markedly
reduce nephrotoxicity and neurotoxicity – dose-limiting factors of
CDDP, while preserving antitumour activity, which was equivalent
to or better than that of free CDDP.
Nephrotoxicity of CDDP is considered to depend on the peak
urinary CDDP concentration and on the maximum CDDP
concentration in the uriniferous tubules (Levi et al, 1982). We
consider that the reduced nephrotoxicity of NC-6004 may be
explained by the following facts: (1) the tendency of micelles to be
less prone to filtration by nephrons because of the NC-6004
particle size (approximately 30nm), and (2) the much lower Cmax
value for CDDP at least in the uriniferous tubules than the value
following CDDP administration. NC-6004 possibly facilitates
treatment on an outpatient basis because it allows safer adminis-
tration to patients with decreased renal function and requires no
massive fluid replacement to protect renal tissue after the
administration of CDDP.
The main neuropathy of CDDP is sensory peripheral neuropathy
(van der Hoop et al, 1990; Gregg et al, 1992). A delay in SNCV due
to the injury of dorsal root ganglia and peripheral nerve has
previously been reported in rats given CDDP, although MNCV was
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Figure 5 Neurotoxicity of CDDP and NC-6004 in rats. Rats (n¼5) were given CDDP (2mgkg
 1), NC-6004 (an equivalent dose of 2mgkg
 1 CDDP),
or 5% glucose, all i.v. twice a week, 11 administrations in total. (A) Sensory nerve conduction velocity and MNCV of the sciatic nerve at week 6 after the
initial administration (control ( ), CDDP (K), and NC-6004 (&)). Histopathological changes of the sciatic nerve were examined by electron microscopy
after the administration of CDDP (B) and NC-6004 (C). In rats given CDDP, widespread degenerations as indicated by loss of microtubules, loss of
filaments, degeneration in the cytoplasm of Schwann cells ( ), and an irregular inner loop ( ) were seen. On the other hand, animals given NC-6004
exhibited nearly normal electron micrographs of the sciatic nerve as the control animals. (D) Changes in relative body weight. Data were derived from the
same rats as those used in the present study (control ( ), CDDP (K), and NC-6004 (J)). (E) The Pt concentration in the sciatic nerve. Rats were given
CDDP (’)( 5 m g k g
 1, n¼5), NC-6004 (&) (an equivalent dose of 5mgkg
 1 CDDP, n¼5), or 5% glucose (n¼2), all i.v. twice a week, four
administrations in total. On day 3 after the final administration, a segment of the sciatic nerve was removed and the Pt concentration in the sciatic nerve was
measured by ICP-MS. Body weight changes are expressed as the mean7s.e. The other data are expressed as the mean7s.d. *Po0.05, **Po0.001, NS: not
significant.
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spreserved in the tail and hind paws of rats (McKeage et al, 1994;
Tredici et al, 1998; Meijer et al, 1999; Tredici et al, 1999).
Furthermore, histopathological examination revealed degenerative
changes in the sciatic nerve in similar experimental animals
(Cavaletti et al, 1992; Tredici et al, 1999). In the present study,
animals given NC-6004 showed no delay in the SNCV, while
animals given CDDP showed a significant delay in the SNCV as
compared with animals given NC-6004. Neuropathologically,
neuronal degeneration, which was observed following CDDP
administration, was not observed with NC-6004 administration.
This result is considered attributable principally to the fact that
the peripheral nerve concentration of Pt decreased to half or less
following NC-6004 administration than with CDDP administration.
The nervous tissue concentration of Pt at the time of NC-6004
administration decreased significantly despite the fact that the
plasma AUC at the time of NC-6004 administration was high, being
65-fold higher than the plasma AUC concentration with CDDP
administration. We consider that this result is attributed to the
marked inhibition of Pt distribution into nervous tissue in the NC-
6004 administration groups as manifested by Vss of 3.0070.61 and
0.0470.0023lkg
 1 in the CDDP and NC-6004 groups, respectively.
In any event, we believe that the neurotoxicity of CDDP reduced by
NC-6004 allows its long-term administration.
On the other hand, transient hepatic dysfunction was observed
in rats. This observation indicates the proneness of Pt to
accumulate in the RES of the liver because NC-6004 is, after all,
said and done, a macromolecule, although preserving a stealth
effect through its outer shell of PEG. We consider that caution
should be exercised against hepatic dysfunction in conducting a
clinical trial of NC-6004 in the future. However, the accumulation
of Pt was lower following NC-6004 administration due to a
decrease in Vss in other organs including nerve. As shown by
changes in body weight in multiple dose studies in rats, the NC-
6004 administration groups have been demonstrated to show a
smaller decrease in body weight as compared with the CDDP
administration groups. In single-dose studies, furthermore, one
dose of CDDP 10mgkg
 1 was equivalent to the 50% of the lethal
dose. In fact, four of 12 animals died within 7 days after
administration. However, none of the eight animals in the NC-
6004 group died after the administration of NC-6004 at a CDDP
equivalent dose of 15mgkg
 1. In terms of haematological toxicity,
there was no significant difference between the CDDP and NC-
6004 groups in rats (data not shown).
In murine tumour strains, CDDP-incorporating polymeric
micelles showed significantly high antitumour activity (Nishiyama
et al, 2003). In the human gastric cancer strain used in the present
study, however, no significant difference was found between the
NC-6004 and CDDP administration groups. A significant differ-
ence was found in antitumour activity between the NC-6004 low-
dose group (2.5mgkg
 1 administration group) and the control
group, while no significant difference was found between the
CDDP low-dose group (2.5mgkg
 1 administration group) and the
control group. Results available to date and the results from the
present study lead to the consideration that the incorporation of
CDDP into polymeric micelles does not reduce its antitumour
activity.
Data from the present study warrant the clinical evaluation of
NC-6004. We consider that the protocol for the Phase I clinical trial
of NC-6004 should employ a regimen without massive i.v. drip
infusion.
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